Centogene N V's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Centogene N V (CNTG) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Centogene N V vs Its Competitors
- TTM: Trailing 12-month revenue of 105M vs 21,369M combined for tracked competitors (0.5% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+107.6% annualized vs trailing 12 months), vs decelerating (-25.1%) for its tracked peer group.
- Growth: Centogene N V generated 2.2% revenue growth year over year in Q4 2023, vs 6.0% for its tracked competitors combined.
- Profitability: Its -73.3% net margin compares with -14.9% for the peer group.
- Peer revenue share: Centogene N V accounted for 1.3% of combined revenue among its tracked peer group, down from 1.4% a year earlier.
- Peer differentiation: Revenue per employee of $0.26M compares with $0.27M for the peer group (1.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
CNTG Sales vs. its Competitors, Q4 2023
Centogene N V reported revenue growth of 2.16 % year on year in Q4 2023, below its competitors' combined revenue growth of 5.98 %.
With a net margin of -73.26 %, Centogene N V reported lower profitability than its competitors (-14.91 %).
Centogene N V generated 1.34 % of the combined sales of its peer group, down from 1.39 % a year earlier.
Centogene N V vs. its Competitors, Q4 2023
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Centogene N V reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Centogene N V and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Centogene N v | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (1) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Centogene N V's competitor groups requires a Commercial License.
For context: the Medical Laboratories industry grew revenue 7.3% year over year, combined, vs 2.2% for Centogene N V. Centogene N V's share of combined industry revenue moved from 0.10% to 0.09%, a gain of 0.00 percentage points.
Centogene N V's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Centogene N v | No | Yes | No | No |
| Competitors combined (16) | ||||
| High-Confidence Competitors (2) | ||||
| Similar Growth & Profitability (8) | 85.70 % (6 of 7) | 75.00 % (6 of 8) | 62.50 % (5 of 8) | 25.00 % (2 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CNTG Stock Performance relative to its Competitors
CNTG Stock Performance relative to High-Confidence Competitors
CNTG Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Caredx Inc | 282.9% | Outperformed |
| 2 | Exact Sciences Corporation | 282.9% | Outperformed |
| 3 | Guardant Health Inc | 282.9% | Outperformed |
| 4 | Natera Inc | 282.9% | Outperformed |
| 5 | Personalis Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Centogene N V's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Centogene N V's Comment on Competition and Industry Peers
Publicly Traded Peers of Centogene N v
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Centogene N v | 9.01 | 104.67 |
| Natera Inc | 57,877.55 | 2,707.08 |
| Quest Diagnostics Inc | 27,091.68 | 11,841.00 |
| Guardant Health Inc | 22,465.15 | 1,183.11 |
| Exact Sciences Corporation | 19,599.02 | 3,245.31 |
| Veracyte Inc | 3,933.11 | 544.74 |
| SUBTOTAL | 137,578.09 | 21,947.57 |
Sign in to see all competitors of Centogene N v .
Sources: Centogene N v's official press releases and company reports; CSIMarket.com's market research; and the company reports and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Centogene N v versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Centogene N V's Competitors Named by the Company
Competitive relationships identified from Centogene N V reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Takeda | Company report | 85% |
| Genedx Holdings Corp | Company report | 85% |
| Invitae Corporation | Company report | 85% |
| Personalis Inc | Company report | 85% |
| Fulgent Genetics Inc | Company report | 85% |
| Caredx Inc | Company report | 85% |
| Burning Rock Biotech Limited | Company report | 85% |
| Myriad Genetics Inc | Company report | 85% |
| Sera Prognostics Inc | Company report | 85% |
| Guardant Health Inc | Company report | 85% |
| Mdxhealth Sa | Company report | 85% |
| Exact Sciences Corporation | Company report | 85% |
| Natera Inc | Company report | 85% |
| Veracyte Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Centogene N V's named competitors require a Commercial License.
Methodology: relationships are extracted from Centogene N V reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.
Centogene N V's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Natera Inc | Reportable 100.00 % |
| Quest Diagnostics Inc | Diagnostic Information Services Business 98.00 % |
| Guardant Health Inc | Reportable 100.00 % |
| Veracyte Inc | Reportable 100.00 % |
| Caredx Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Centogene N V's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Centogene N v | 9 | 261,681 | -96,084 |
| Natera Inc | 57,878 | 440,892 | -31,327 |
| Quest Diagnostics Inc | 27,092 | 207,737 | 20,456 |
| Guardant Health Inc | 22,465 | 472,109 | -180,940 |
| Exact Sciences Corporation | 19,599 | 450,738 | -28,882 |
| Veracyte Inc | 3,933 | 721,503 | 151,633 |
| PEERS TOTAL | 137,569 | 272,182 | -16,807 |
Centogene N V's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Natera Inc | United States 98.24 % |
| Guardant Health Inc | United States 94.35 % |
| Exact Sciences Corporation | United States 93.11 % |
| Caredx Inc | United States 96.56 % |
| Fulgent Genetics Inc | Other countries 4.93 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Centogene N V's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Laboratories industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (75 companies). See the full Medical Laboratories industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 18.46 % | 34.72 % (avg) | -16.3 pp |
| Operating Margin | -30.65 % | industry median | +0.1 pp |
| EBITDA Margin | -64.13 % | -6.58 % (avg) | -57.6 pp |
| Capital Intensity (Capex / Revenue) | 0.04 % | 7.40 % (avg) | -7.4 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Centogene N V's Valuation vs Competitive Position
Valuation multiples vs the Medical Laboratories industry average (75 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Laboratories industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 34.6x | - |
| EV / EBITDA | - | 19.7x | - |
| P/B | -1.2x | 4.0x | -5.2x |
| Return on Equity | 137.43 % | industry aggregate | 132.97 % |
| Return on Invested Capital | 4,211.11 % | -4.26 % (avg) | 4,215.37 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Centogene N V's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenue Growth | 13.89 % | 0.07 % | 4.65 % |
| Operating Margin | -67.02 % | -38.73 % | -30.65 % |
| Return on Invested Capital | -66.97 % | -78.79 % | 4,211.11 % |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Centogene N V's Strategic Group Map
Every company in Centogene N V's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Centogene N V is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Centogene N V's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.04 % vs industry average 7.40 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Centogene N V's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Centogene N V's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Centogene N V's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Centogene N V falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Centogene N V's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 133.0 points above the industry aggregate.
- Latest-quarter revenue run-rate is accelerating (+107.6% annualized vs trailing 12 months).
Weaknesses
No rule matched.
Opportunities
No rule matched.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-25.1% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Centogene N V's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Centogene N v | 0.44 | 1.02 | - |
| Natera Inc | - | 3.14 | 0.05 |
| Quest Diagnostics Inc | 0.28 | 1.35 | 0.74 |
| Guardant Health Inc | 2.56 | 4.29 | - |
| Exact Sciences Corporation | 1.22 | 2.68 | 0.95 |
| Veracyte Inc | 4.95 | 8.11 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Centogene N V's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Centogene N v | Q4 2023 | +4.7 % | - |
| Natera Inc | Q2 2026 | +37.7 % | - |
| Quest Diagnostics Inc | Q3 2026 | +10.0 % | +20.5 % |
| Guardant Health Inc | Q2 2026 | +44.3 % | - |
| Exact Sciences Corporation | Q4 2025 | +23.1 % | - |
| Veracyte Inc | Q2 2026 | +23.4 % | - |
| PEERS TOTAL | +15.7 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Centogene N V's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Centogene N v | Q4 2023 | +15.9 % | -88.8 % |
| Natera Inc | Q2 2026 | -99.3 % | +144.9 % |
| Quest Diagnostics Inc | Q3 2026 | +10.1 % | +15.3 % |
| Guardant Health Inc | Q2 2026 | +42.8 % | +108.2 % |
| Exact Sciences Corporation | Q4 2025 | +19.5 % | - |
| Veracyte Inc | Q2 2026 | -91.4 % | +122.3 % |
Centogene N V's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Centogene N v | - | - | - |
| Natera Inc | - | - | - |
| Quest Diagnostics Inc | 6.96% | 8.01% | 15.22% |
| Guardant Health Inc | - | - | - |
| Exact Sciences Corporation | - | - | - |
| Veracyte Inc | 8.04% | 8.15% | 8.64% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Centogene N V's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Centogene N v | - | 0.09 |
| Natera Inc | - | 21.38 |
| Quest Diagnostics Inc | 24.36 | 2.29 |
| Guardant Health Inc | - | 18.99 |
| Exact Sciences Corporation | - | 6.04 |
| Veracyte Inc | 33.99 | 7.22 |
| PEERS AVERAGE | - | 6.27 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.